Adalimumab Induction Therapy for Crohn Disease Previously Treated with Infliximab
Mayo Clinic · Imelda Hospital · +4 more institutions
Abstract
Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective treatment for patients with Crohn disease who are naive to the chimeric TNF antagonist, infliximab. No anti-TNF agent has been evaluated prospectively in patients with Crohn disease who had responded to another anti-TNF agent and then lost that response or were intolerant of the agent.
To determine whether adalimumab induces remissions more frequently than placebo in adult patients with Crohn disease who have symptoms despite infliximab therapy or who cannot take infliximab because of adverse events.
Citation impact
- FWCI
- 38.93
- Percentile
- 100%
- References
- 25
Authors
11- WJWilliam J. SandbornCorresponding
Mayo Clinic, Imelda Hospital, University of Calgary, University of Chicago, Universitair Ziekenhuis Leuven, University of British Columbia
- PRPaul Rutgeerts
University of Calgary, Mayo Clinic, University of Chicago, Universitair Ziekenhuis Leuven, Imelda Hospital, University of British Columbia
- RERobert Enns
Universitair Ziekenhuis Leuven, University of British Columbia, Imelda Hospital, University of Calgary, Mayo Clinic, University of Chicago
- SBStephen B. Hanauer
Mayo Clinic, University of Calgary, Universitair Ziekenhuis Leuven, University of British Columbia, University of Chicago, Imelda Hospital
- JCJean‐Frédéric Colombel
Imelda Hospital, University of Chicago, University of British Columbia, Universitair Ziekenhuis Leuven, University of Calgary, Mayo Clinic
Topics & keywords
- Medicine
- Adalimumab
- Infliximab
- Crohn's disease
- Placebo
- Internal medicine
- Adverse effect
- Clinical endpoint
- Good health and well-being